CMCO's Growth and Integration Momentum Continues in Q2 FY27; Increases Full Year Guidance

Columbus McKinnon’s Q2 FY27 net sales rose 107% year over year to $539.3 million, primarily reflecting the Kito Crosby acquisition; orders increased 122%, and adjusted EBITDA rose 176.5% to $111.2 million with a 20.6% margin, up 520 bps. The company reported a $25.5 million attributable net loss and adjusted EPS of $0.61, down $0.01, while saying integration synergies were ahead of plan. CMCO raised FY27 guidance to $2.13–$2.17 billion in sales, $425–$440 million in adjusted EBITDA, and $2.00–$2.15 in adjusted EPS; net leverage was 4.9x.

Analysis

The earnings-quality split matters more than the headline growth: legacy sales advanced only modestly, while acquisition-related adjustments materially support the reported adjusted profit picture. Q2 adjusted EBITDA margin expansion is encouraging, but reported gross margin barely moved; the gap warrants scrutiny of purchase-accounting charges and whether synergies are recurring rather than add-backs. A 1.0x book-to-bill supports revenue conversion, not a fresh acceleration in demand.

Near term, the guidance increase can support the shares, but the balance-sheet constraint limits upside rerating. Net leverage remains elevated, interest expense is large relative to operating profit, and first-half free cash flow was thin after capex and acquisition-related cash costs. Preferred-share dilution also means adjusted EPS is not directly comparable with GAAP per-share earnings. Management’s deleveraging objective depends on cash conversion improving—not simply on adjusted EBITDA growth.

Over 1–3 months, monitor quarterly free cash flow, debt paydown, legacy organic growth, and the reconciliation between adjusted and reported margins. Over 6–18 months, successful integration could improve scale and margins; weaker industrial demand or slower synergy capture would instead expose the debt burden and constrain capital returns. The contrarian risk is treating acquisition-led scale and non-GAAP margin gains as proof of durable organic acceleration. No clear read-through trade in competitors without evidence of displacement or pricing effects.

Key Decisions for Investors

• Do not chase a post-release gap. Consider a small CMCO long only on post-call weakness if management supports the guidance with specific, trackable synergy and cash-conversion milestones; reassess if legacy sales growth stalls or guidance is cut.
• Treat debt reduction and cash generation as the key 1–3 month catalysts: verify quarterly free cash flow turns sustainably positive and net leverage declines. If EBITDA improves but cash conversion remains weak, reduce exposure rather than crediting the deleveraging thesis.
• Avoid valuing CMCO solely on adjusted EPS or EBITDA. Track recurring integration costs, acquisition-related adjustments, and the preferred-share impact on diluted shares; persistent adjustments or limited reported-margin improvement would falsify the margin-expansion case.
• No forced peer or options trade: the release does not establish competitive share gains, and current data do not support a reliable relative-value spread or defined options risk/reward.